Indaptus Therapeutics, Inc. cotiza a 2.44 USD y tiene una capitalización bursátil de $325M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatoce…
| Periodo | 2026-03 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-9.19 | $-2.98 | $-9.09 | $-8.96 |
| Estimado | $-4.36 | $-4.17 | $-9.24 | $-5.04 |
| Sorpresa | -110.8% | +28.5% | +1.6% | -77.8% |
| Métrica | INDP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -661.5% | -40.4% | -621.1% |
| ROA | -223.9% | -32.0% | -191.9% |
| Current Ratio | 1.51 | 2.84 | -1.33 |
| Debt / Equity | — | 0.28 | — |